Literature DB >> 22993591

Effects of irbesartan on 24-h blood pressure changes and urinary albumin levels in Japanese outpatients.

Tadashi Arai1, Mihoko Senda, Hitomi Yokoyama, Kikuko Yasuda.   

Abstract

In Japan, ambulatory blood pressure monitoring (ABPM) became covered by health insurance in April 2008. In The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2009), the importance of 24-h blood pressure monitoring was also described in an additional section. Therefore, ABPM may be increasingly applied in hypertension treatment. However, in Japan, few studies have presented data on the effects of various anti-hypertensive agents on 24-h blood pressure changes. Irbesartan became commercially available in July 2008 as the sixth angiotensin II type 1 receptor blocker in Japan. In the present study, 24-h blood pressure control was examined using ABPM in Japanese patients with essential hypertension who were treated with irbesartan, and its efficacy was evaluated. This study was completed in 30 of the 32 subjects. This agent decreased both the nocturnal and daytime blood pressures and reduced the rate of change in the systolic blood pressure early in the morning, resulting in favorable blood pressure control. It also significantly decreased the urinary albumin level, suggesting that it exhibits renoprotective effects at doses approved in Japan.

Entities:  

Year:  2010        PMID: 22993591      PMCID: PMC3445921          DOI: 10.3892/etm_00000105

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  15 in total

1.  Device for the self-measurement of blood pressure that can monitor blood pressure during sleep.

Authors:  K Chonan; M Kikuya; T Araki; T Fujiwara; M Suzuki; M Michimata; J Hashimoto; T Ohkubo; A Hozawa; N Yamamoto; Y Miyawaki; M Matsubara; Y Imai
Journal:  Blood Press Monit       Date:  2001-08       Impact factor: 1.444

2.  The influence of work- and home-related stress on the levels and diurnal variation of ambulatory blood pressure and neurohumoral factors in employed women.

Authors:  Kazuomi Kario; Gary D James; RoseMerie Marion; Mustafa Ahmed; Thomas G Pickering
Journal:  Hypertens Res       Date:  2002-07       Impact factor: 3.872

3.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

4.  Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study.

Authors:  Takayoshi Ohkubo; Masahiro Kikuya; Hirohito Metoki; Kei Asayama; Taku Obara; Junichiro Hashimoto; Kazuhito Totsune; Haruhisa Hoshi; Hiroshi Satoh; Yutaka Imai
Journal:  J Am Coll Cardiol       Date:  2005-08-02       Impact factor: 24.094

5.  Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects.

Authors:  M R Marino; K Langenbacher; N F Ford; H D Uderman
Journal:  J Clin Pharmacol       Date:  1998-03       Impact factor: 3.126

6.  Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist.

Authors:  C Cazaubon; J Gougat; F Bousquet; P Guiraudou; R Gayraud; C Lacour; A Roccon; G Galindo; G Barthelemy; B Gautret
Journal:  J Pharmacol Exp Ther       Date:  1993-05       Impact factor: 4.030

Review 7.  Irbesartan: a review of its use in hypertension and diabetic nephropathy.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring.

Authors:  Maria Jose Fabia; Noelia Abdilla; Rosa Oltra; Conrado Fernandez; Josep Redon
Journal:  J Hypertens       Date:  2007-07       Impact factor: 4.844

9.  Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension.

Authors:  A H van den Meiracker; P J Admiraal; J A Janssen; J M Kroodsma; W A de Ronde; F Boomsma; J Sissmann; P J Blankestijn; P G Mulder; A J Man In 't Veld
Journal:  Hypertension       Date:  1995-01       Impact factor: 10.190

10.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.